GPs warned QRISK could increase statins scrips

The introduction of QRISK as the cardiovascular risk tool for England and Wales could increase the use of statins, cardiovascular experts have warned.

Draft lipid modification guidance issued last week by NICE recommends the use of QRISK over the currently used Framingham tool, which is known to overestimate cardiovascular risk in the UK population.

Despite this, Professor Julia Hippisley-Cox, co-author of QRISK and a GP in Nottingham, said QRISK will boost, rather than reduce, the number of patients taking statins.

‘QRISK will increase the number of patients from deprived areas and the number of women that will require statins,'she explained.

‘Patients that have already been identified as being at high risk of cardiovascular disease (CVD) will remain on statins, so QRISK will not take any patients off statins.'

Dr Terry McCormack, chairman of the Primary Care Cardiovascular Society (PCCS) and a GP in Whitby, said statin prescribing for primary prevention is underused in the UK.

sanjay.tanday@haymarket.com

Comment below and tell us what you think 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus